Akums Drugs & Pharmaceuticals Limited reported a strong financial performance for the second quarter of FY27, with consolidated profit after tax (PAT) increasing 168% year-on-year (YoY) to ₹115 crore, compared with ₹43 crore in Q2 FY26.
The pharmaceutical contract development and manufacturing organisation (CDMO) reported consolidated revenue of ₹1,342 crore for the quarter ended September 30, 2026, registering a growth of 31.9% against ₹1,018 crore in the corresponding quarter of the previous financial year.
The company’s operating performance also improved significantly, with EBITDA more than doubling to ₹195 crore from ₹94 crore a year ago. EBITDA margin expanded to 14.5% from 9.3% in Q2 FY26.
The growth was primarily supported by the company’s CDMO business, which continued to benefit from customer demand, higher volumes and improved operating performance.
Akums Drugs Q2 Results : Key Financial Highlights
Consolidated Performance – Q2 FY27
- Revenue: ₹1,342 crore, up 31.9% YoY.
- EBITDA: ₹195 crore, up 106% YoY.
- EBITDA Margin: 14.5%, compared with 9.3% in Q2 FY26.
- Profit After Tax (PAT): ₹115 crore, up 168% YoY.
- PAT Margin: 8.4%, compared with 4.1% in the corresponding quarter last year.
First-Half Performance – H1 FY27
- Revenue: ₹2,509 crore, compared with ₹2,042 crore in H1 FY26.
- EBITDA: ₹369 crore, compared with ₹223 crore in the year-ago period.
- PAT: ₹216 crore, compared with ₹107 crore in H1 FY26.
- EBITDA Margin: 14.7%, against 10.9% in H1 FY26.
CDMO Business Remains the Key Growth Driver
Akums’ contract development and manufacturing business remained the primary contributor to its quarterly performance.
CDMO revenue increased 38.6% YoY to ₹1,115 crore in Q2 FY27, compared with ₹804 crore in the corresponding quarter last year. The segment contributed approximately 83% of the company’s consolidated revenue.
CDMO EBITDA also nearly doubled to ₹168 crore from ₹84 crore in Q2 FY26. Its EBITDA margin improved to 15.1% from 10.5% a year ago.
The company attributed the improvement to healthy customer demand, double-digit volume growth, better capacity utilisation and improved operating performance.
Akums Expands into Colour Cosmetics Manufacturing
During the quarter, Akums expanded its manufacturing presence beyond pharmaceuticals by acquiring Oriflame India’s manufacturing business for ₹56 crore through its wholly owned subsidiary, Pure & Cure Healthcare Private Limited.
The transaction includes two manufacturing facilities located in Roorkee, Uttarakhand, and Noida, Uttar Pradesh, along with a leased warehouse in Noida.
The acquisition marks Akums’ entry into colour cosmetics manufacturing and provides an opportunity to expand its capabilities across skincare, wellness and beauty products.
API Business and International Expansion
The company also reported developments across its other business operations. Its API business continued to face challenges, with API revenue declining 35.3% YoY to ₹29 crore during the quarter.
Meanwhile, Akums is working to expand its international CDMO presence. According to management commentary, the company has a pipeline of more than 30 products for European markets.
Its Zambia initiative is expected to begin commercial supplies from India in Q4 FY27, with revenue contribution anticipated from Q1 FY28.
Conclusion
Akums Drugs & Pharmaceuticals delivered strong year-on-year growth in Q2 FY27, with revenue increasing 31.9% and net profit rising 168%. Improved CDMO performance, higher EBITDA and expansion into colour cosmetics manufacturing were among the key developments during the quarter.
The improvement in operating margins and growth in the CDMO business were important contributors to the company’s financial performance.
Source: Akums Drugs & Pharmaceuticals Limited’s unaudited consolidated financial results, board meeting outcome and press release filed with NSE and BSE on November 2, 2026.
Disclaimer: Investments in the securities market are subject to market risks. Read all related documents carefully before investing.
If you want to know which upcoming Q2 earnings reports are dropping? Check out Upcoming Q2 Results
Do you have a news tip for Lakshmishree reporters? Please email us at [email protected]
News Desk
